Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers

Sevil Sadri; İpek Yönal Hindilerden; Yaşa Gül Mutlu; Tarık Onur Tiryaki; Ali İhsan Gemici; Huseyin Saffet Bekoz; Ömür Gökmen Sevindik; Fehmi Hindilerden; Sevgi Kalayoğlu-beşışık; Meliha Nalçacı; Deniz Sargın

Article Details

Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers

Authors:

Sevil Sadri | İpek Yönal Hindilerden | Yaşa Gül Mutlu | Tarık Onur Tiryaki | Ali İhsan Gemici | Huseyin Saffet Bekoz | Ömür Gökmen Sevindik | Fehmi Hindilerden | Sevgi Kalayoğlu-beşışık | Meliha Nalçacı | Deniz Sargın

Publisher:

Prusa Medical Publishing

Main Topics:

Clinical Sciences | Haematology

Journal:

The European Research Journal Vol.9 Issue 6, pp.1368-1379

Document Type:

Article

Publication Date:

4/2023

Document Language:

English

Document ID (Org No.):

2001294098

pISSN:

2149-3189

Keywords:

Abstract:

 Objectives: The main objective of the present study was to evaluate whether the use of plerixafor in combination with granulocyte colony-stimulating factor G-CSF or subsequent use of isolated G-CSF and then plerixafor following disease-specific chemotherapy, and whether it would allow for adequate peripheral stem cell collection in patients. Methods: The retrospective study evaluated 54 patients with previous mobilization failure who were administered plerixafor in 2 centers. In patients without any side effects, CD 34 cell counts, the percentage of patients who were found eligible for autologous transplantation, the engraftment kinetics of the patients who underwent transplantation, and their overall survival results were compared between the two groups where G-CSF was used with plerixafor, or where plerixafor was used after isolated G-CSF following chemotherapy. Results: The median age of the patients was 49 years range: 17-70, and 64.8 n  35 were males. It was identified that 31 57.4 patients underwent mobilization treatment with isolated G-CSF and plerixafor, and 23 42.6 patients underwent mobilization treatment with chemotherapy plus G-CSF and plerixafor. In all patients, mean hemoglobin level 11.3  1.5 gdL vs. 9.3  1.3 gdL; p  0.001 and median platelet level 129.2 10 3 µL vs. 58.4 10 3 µL were found to be higher, while febrile neutropenia rate 3.3 vs. 60.9, the percentage of replacement patients 6.7 vs. 65.2, and median days of G-CSF 6 vs. 9 were found to be lower on the day of plerixafor administration in the isolated G-CSF and plerixafor group compared to the chemotherapy and G-CSF and plerixafor group. Conclusions: In conclusion, our study demonstrated that administration of plerixafor is generally safe and well-tolerated. Regardless of the underlying disease, it offers an effective alternative for patients with previous failed mobilization attempts using conventional regimens, and allows stem cell collection with fewer apheresis sessions.

 Objectives: The main objective of the present study was to evaluate whether the use of plerixafor in combination with granulocyte colony-stimulating factor G-CSF or subsequent use of isolated G-CSF and then plerixafor following disease-specific chemotherapy, and whether it would allow for adequate peripheral stem cell collection in patients. Methods: The retrospective study evaluated 54 patients with previous mobilization failure who were administered plerixafor in 2 centers. In patients without any side effects, CD 34 cell counts, the percentage of patients who were found eligible for autologous transplantation, the engraftment kinetics of the patients who underwent transplantation, and their overall survival results were compared between the two groups where G-CSF was used with plerixafor, or where plerixafor was used after isolated G-CSF following chemotherapy. Results: The median age of the patients was 49 years range: 17-70, and 64.8 n  35 were males. It was identified that 31 57.4 patients underwent mobilization treatment with isolated G-CSF and plerixafor, and 23 42.6 patients underwent mobilization treatment with chemotherapy plus G-CSF and plerixafor. In all patients, mean hemoglobin level 11.3  1.5 gdL vs. 9.3  1.3 gdL; p  0.001 and median platelet level 129.2 10 3 µL vs. 58.4 10 3 µL were found to be higher, while febrile neutropenia rate 3.3 vs. 60.9, the percentage of replacement patients 6.7 vs. 65.2, and median days of G-CSF 6 vs. 9 were found to be lower on the day of plerixafor administration in the isolated G-CSF and plerixafor group compared to the chemotherapy and G-CSF and plerixafor group. Conclusions: In conclusion, our study demonstrated that administration of plerixafor is generally safe and well-tolerated. Regardless of the underlying disease, it offers an effective alternative for patients with previous failed mobilization attempts using conventional regimens, and allows stem cell collection with fewer apheresis sessions.

 Objectives: The main objective of the present study was to evaluate whether the use of plerixafor in combination with granulocyte colony-stimulating factor G-CSF or subsequent use of isolated G-CSF and then plerixafor following disease-specific chemotherapy, and whether it would allow for adequate peripheral stem cell collection in patients. Methods: The retrospective study evaluated 54 patients with previous mobilization failure who were administered plerixafor in 2 centers. In patients without any side effects, CD 34 cell counts, the percentage of patients who were found eligible for autologous transplantation, the engraftment kinetics of the patients who underwent transplantation, and their overall survival results were compared between the two groups where G-CSF was used with plerixafor, or where plerixafor was used after isolated G-CSF following chemotherapy. Results: The median age of the patients was 49 years range: 17-70, and 64.8 n  35 were males. It was identified that 31 57.4 patients underwent mobilization treatment with isolated G-CSF and plerixafor, and 23 42.6 patients underwent mobilization treatment with chemotherapy plus G-CSF and plerixafor. In all patients, mean hemoglobin level 11.3  1.5 gdL vs. 9.3  1.3 gdL; p  0.001 and median platelet level 129.2 10 3 µL vs. 58.4 10 3 µL were found to be higher, while febrile neutropenia rate 3.3 vs. 60.9, the percentage of replacement patients 6.7 vs. 65.2, and median days of G-CSF 6 vs. 9 were found to be lower on the day of plerixafor administration in the isolated G-CSF and plerixafor group compared to the chemotherapy and G-CSF and plerixafor group. Conclusions: In conclusion, our study demonstrated that administration of plerixafor is generally safe and well-tolerated. Regardless of the underlying disease, it offers an effective alternative for patients with previous failed mobilization attempts using conventional regimens, and allows stem cell collection with fewer apheresis sessions.

 Objectives: The main objective of the present study was to evaluate whether the use of plerixafor in combination with granulocyte colony-stimulating factor G-CSF or subsequent use of isolated G-CSF and then plerixafor following disease-specific chemotherapy, and whether it would allow for adequate peripheral stem cell collection in patients. Methods: The retrospective study evaluated 54 patients with previous mobilization failure who were administered plerixafor in 2 centers. In patients without any side effects, CD 34 cell counts, the percentage of patients who were found eligible for autologous transplantation, the engraftment kinetics of the patients who underwent transplantation, and their overall survival results were compared between the two groups where G-CSF was used with plerixafor, or where plerixafor was used after isolated G-CSF following chemotherapy. Results: The median age of the patients was 49 years range: 17-70, and 64.8 n  35 were males. It was identified that 31 57.4 patients underwent mobilization treatment with isolated G-CSF and plerixafor, and 23 42.6 patients underwent mobilization treatment with chemotherapy plus G-CSF and plerixafor. In all patients, mean hemoglobin level 11.3  1.5 gdL vs. 9.3  1.3 gdL; p  0.001 and median platelet level 129.2 10 3 µL vs. 58.4 10 3 µL were found to be higher, while febrile neutropenia rate 3.3 vs. 60.9, the percentage of replacement patients 6.7 vs. 65.2, and median days of G-CSF 6 vs. 9 were found to be lower on the day of plerixafor administration in the isolated G-CSF and plerixafor group compared to the chemotherapy and G-CSF and plerixafor group. Conclusions: In conclusion, our study demonstrated that administration of plerixafor is generally safe and well-tolerated. Regardless of the underlying disease, it offers an effective alternative for patients with previous failed mobilization attempts using conventional regimens, and allows stem cell collection with fewer apheresis sessions.

Article Details

Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers

Authors:

Sevil Sadri | İpek Yönal Hindilerden | Yaşa Gül Mutlu | Tarık Onur Tiryaki | Ali İhsan Gemici | Huseyin Saffet Bekoz | Ömür Gökmen Sevindik | Fehmi Hindilerden | Sevgi Kalayoğlu-beşışık | Meliha Nalçacı | Deniz Sargın

Publisher:

Prusa Medical Publishing

Main Topics:

Clinical Sciences | Haematology

Journal:

The European Research Journal Vol.9 Issue 6, pp.1368-1379

Document Type:

Article

Publication Date:

4/2023

Document Language:

English

Document ID (Org No.):

2001294098

pISSN:

2149-3189

Autologous stem cell transplantation

mobilization

plerixafor

Issues

Article Details

Comparison of different plerixafor-based strategies for adequate hematopoietic stem cell collection in poor mobilizers

Authors: Sevil Sadri | İpek Yönal Hindilerden | Yaşa Gül Mutlu | Tarık Onur Tiryaki | Ali İhsan Gemici | Huseyin Saffet Bekoz | Ömür Gökmen Sevindik | Fehmi Hindilerden | Sevgi Kalayoğlu-beşışık | Meliha Nalçacı | Deniz Sargın

Publisher: Prusa Medical Publishing

Main Topics: Clinical Sciences | Haematology

Journal: The European Research Journal Vol.9 Issue 6, pp.1368-1379

Document Type: Article

Publication Date: 4/2023

Document Language: English

Document ID (Org No.): 2001294098

pISSN: 2149-3189

Autologous stem cell transplantation

mobilization

plerixafor

Issues

Authors:

Sevil Sadri | İpek Yönal Hindilerden | Yaşa Gül Mutlu | Tarık Onur Tiryaki | Ali İhsan Gemici | Huseyin Saffet Bekoz | Ömür Gökmen Sevindik | Fehmi Hindilerden | Sevgi Kalayoğlu-beşışık | Meliha Nalçacı | Deniz Sargın

Publisher:

Prusa Medical Publishing

Main Topics:

Clinical Sciences | Haematology

Journal:

The European Research Journal Vol.9 Issue 6, pp.1368-1379

Document Type:

Article

Publication Date:

4/2023

Document Language:

English

Document ID (Org No.):

2001294098

pISSN:

2149-3189